Stock Analysis on Net
Stock Analysis on Net

Biogen Inc. (NASDAQ:BIIB)

This company has been moved to the archive! The financial data has not been updated since October 25, 2022.

Common-Size Income Statement
Quarterly Data

Biogen Inc., common-size consolidated income statement (quarterly data)

Microsoft Excel
3 months ended: Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Product, net 78.22 79.37 81.61 80.24 79.37 80.58 82.10 80.68 79.69 75.94 82.18 79.67 80.41 79.64 76.80 80.13 80.84 82.15 80.59 82.02 85.21 85.75 84.68
Revenues from anti-CD20 therapeutic programs 16.62 16.85 15.78 15.15 14.95 15.86 14.44 14.69 16.59 12.99 14.72 16.36 16.55 15.94 14.83 15.17 14.88 14.61 14.15 12.55 13.21 12.90 12.12
Other 5.16 3.78 2.61 4.62 5.68 3.57 3.46 4.63 3.72 11.07 3.09 3.97 3.04 4.42 8.38 4.70 4.28 3.24 5.25 5.43 1.59 1.35 3.20
Revenue 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Cost of sales, excluding amortization and impairment of acquired intangible assets -18.72 -18.69 -29.78 -24.15 -18.42 -16.57 -17.75 -17.20 -13.30 -11.17 -12.85 -12.18 -11.94 -13.17 -17.25 -13.85 -13.40 -12.54 -14.24 -15.40 -12.02 -11.90 -13.68
Gross profit 81.28% 81.31% 70.22% 75.85% 81.58% 83.43% 82.25% 82.80% 86.70% 88.83% 87.15% 87.82% 88.06% 86.83% 82.75% 86.15% 86.60% 87.46% 85.76% 84.60% 87.98% 88.10% 86.32%
Research and development -21.89 -20.42 -21.79 -25.59 -25.28 -21.08 -19.09 -60.51 -33.79 -17.59 -13.48 -18.84 -15.01 -13.40 -16.15 -17.34 -14.77 -29.23 -15.86 -17.77 -14.50 -25.86 -15.06
Selling, general and administrative -22.46 -22.12 -25.08 -28.82 -23.54 -22.97 -22.09 -28.26 -16.98 -15.08 -16.13 -18.11 -15.40 -16.25 -16.27 -16.76 -14.47 -15.38 -16.01 -17.31 -14.09 -13.97 -17.76
Amortization and impairment of acquired intangible assets -2.25 -2.61 -2.64 -2.49 -3.99 -21.77 -3.64 -8.74 -2.45 -1.67 -2.02 -1.84 -7.89 -1.94 -1.95 -7.21 -8.20 -3.20 -3.32 -4.23 -3.54 -3.82 -15.96
Collaboration (profit) loss sharing -1.81 -1.14 4.63 2.46 -0.76 0.55 -2.54 -2.32 -2.16 -0.59 -2.03 -1.63 -1.67 -1.76 -1.66 -1.58 -1.38 -1.17 -1.36 -0.90 -1.14 -0.86 -0.74
Gain (loss) on divestiture of Hillerød, Denmark manufacturing operations 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.24 0.00 0.00 0.00 1.09 0.49 0.06 -3.31 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Gain (loss) on fair value remeasurement of contingent consideration 0.08 0.17 0.28 0.06 0.56 -0.01 1.25 2.20 0.86 -0.27 0.13 -0.07 1.61 0.55 -0.33 -2.25 2.56 -0.06 0.18 -0.05 -0.97 -0.69 -0.36
Acquired in-process research and development 0.00 0.00 0.00 0.00 0.00 -0.65 0.00 0.00 0.00 0.00 -2.12 0.00 0.00 0.00 0.00 0.00 -0.80 -2.23 -0.32 0.00 0.00 -3.90 0.00
Restructuring charges -0.61 -2.73 -1.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.01 -0.02 -0.01 -0.08 -0.17 -0.05 -0.05 -0.03 0.00 0.00 0.00
Gain on sale of building 20.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Income from operations 52.43% 32.48% 24.12% 21.48% 28.57% 17.50% 36.15% -11.59% 32.18% 53.63% 51.49% 48.42% 50.17% 54.08% 43.06% 40.92% 49.36% 36.14% 49.01% 44.32% 53.72% 39.00% 36.44%
Other income (expense), net 2.23 16.55 -10.40 -6.66 -18.10 3.47 -18.82 23.96 -3.81 1.71 -3.41 -1.34 -0.76 -5.46 10.24 -0.81 3.35 -1.03 -1.31 -2.00 -1.42 -2.22 -1.34
Income before equity in income (loss) of investee and income tax (expense) benefit 54.66% 49.03% 13.72% 14.81% 10.48% 20.98% 17.33% 12.37% 28.37% 55.34% 48.08% 47.08% 49.42% 48.62% 53.30% 40.11% 52.71% 35.12% 47.71% 42.33% 52.31% 36.79% 35.11%
Equity in income (loss) of investee, net of tax 0.00 0.23 -0.13 0.65 0.04 1.24 -0.68 0.63 -0.39 0.41 -0.42 -0.34 -0.61 -0.45 -0.82 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Income before income tax (expense) benefit 54.66% 49.26% 13.59% 15.46% 10.51% 22.21% 16.66% 13.00% 27.98% 55.75% 47.66% 46.74% 48.81% 48.17% 52.48% 40.11% 52.71% 35.12% 47.71% 42.33% 52.31% 36.79% 35.11%
Income tax (expense) benefit -9.42 -8.37 -4.96 -16.22 0.93 14.74 -1.64 -0.47 -7.13 -12.12 -8.26 -7.52 -5.87 -6.86 -12.11 -13.32 -10.75 -7.86 -10.30 -47.36 -12.47 -8.76 -8.51
Net income 45.24% 40.89% 8.63% -0.75% 11.45% 36.95% 15.02% 12.53% 20.85% 43.64% 39.40% 39.21% 42.94% 41.31% 40.37% 26.80% 41.96% 27.26% 37.41% -5.03% 39.84% 28.03% 26.59%
Net (income) loss attributable to noncontrolling interests, net of tax -0.01 -0.03 3.37 14.22 0.40 -20.79 0.21 0.01 -0.07 -1.75 0.18 0.00 0.00 0.00 0.00 0.05 0.04 -1.44 0.05 -3.96 0.00 0.00 0.00
Net income attributable to Biogen Inc. 45.23% 40.86% 12.00% 13.47% 11.85% 16.16% 15.23% 12.55% 20.78% 41.89% 39.59% 39.21% 42.94% 41.31% 40.37% 26.85% 42.00% 25.82% 37.46% -8.99% 39.84% 28.03% 26.60%

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

Income statement item Description The company
Income from operations The net result for the period of deducting operating expenses from operating revenues. Biogen Inc. income from operations as a percentage of revenue increased from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.
Income before income tax (expense) benefit Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Biogen Inc. income before income tax (expense) benefit as a percentage of revenue increased from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.
Net income attributable to Biogen Inc. The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Biogen Inc. net income attributable to Biogen Inc. as a percentage of revenue increased from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.